En­livex’s shares cut in half af­ter ‘bi­as­es’ cloud Ph2 cell ther­a­py da­ta in sep­sis

En­livex Ther­a­peu­tics’ cell ther­a­py has dis­ap­point­ed in­vestors be­cause its im­pact in a mid-stage test in sep­sis was dif­fi­cult to fig­ure out. The com­pa­ny nonethe­less said its can­di­date could have po­ten­tial in sep­sis specif­i­cal­ly due to uri­nary tract in­fec­tion.

The Is­rael-based com­pa­ny is study­ing its off-the-shelf cell ther­a­py de­signed to re­store macrophage home­osta­sis. In sep­sis, macrophages are re­pro­grammed out of their home­o­sta­t­ic state, con­tribut­ing to dis­ease sever­i­ty, En­livex said.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER